CovidFranceV1, Main, Exploration, bibRecord, 000647

Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19.

Identifieur interne : 000647 ( Main/Exploration ); précédent : 000646; suivant : 000648

Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19.

Auteurs : Alex C. Spyropoulos [États-Unis] ; Jerrold H. Levy [États-Unis] ; Walter Ageno [Italie] ; Jean Marie Connors [États-Unis] ; Beverley J. Hunt [Royaume-Uni] ; Toshiaki Iba [Japon] ; Marcel Levi [Royaume-Uni] ; Charles Marc Samama [France] ; Jecko Thachil [Royaume-Uni] ; Dimitrios Giannis [États-Unis] ; James D. Douketis [Canada]

Source :

Journal of thrombosis and haemostasis : JTH [ 1538-7836 ] ; 2020.

RBID : pubmed:32459046

Descripteurs français

KwdFr :
- Analyse sur le lieu d'intervention (MeSH), Anticoagulants (administration et posologie), Anticoagulants (effets indésirables), Anticoagulants (usage thérapeutique), Betacoronavirus (MeSH), Calendrier d'administration des médicaments (MeSH), Dépistage de masse (MeSH), Humains (MeSH), Hémorragie (induit chimiquement), Hémorragie (prévention et contrôle), Infections à coronavirus (complications), Infections à coronavirus (diagnostic), Infections à coronavirus (sang), Marqueurs biologiques (MeSH), Oedème pulmonaire (sang), Oedème pulmonaire (étiologie), Pandémies (MeSH), Patients hospitalisés (MeSH), Pneumopathie virale (complications), Pneumopathie virale (sang), Post-cure (MeSH), Prise en charge de la maladie (MeSH), Produits de dégradation de la fibrine et du fibrinogène (analyse), Sensibilité et spécificité (MeSH), Soins de réanimation (MeSH), Techniques de diagnostic cardiovasculaire (MeSH), Techniques de laboratoire clinique (MeSH), Thromboembolisme veineux (diagnostic), Thromboembolisme veineux (prévention et contrôle), Thromboembolisme veineux (thérapie), Thromboembolisme veineux (étiologie), Thrombophilie (sang), Thrombophilie (traitement médicamenteux), Thrombophilie (étiologie).
MESH :
- administration et posologie : Anticoagulants.
- analyse : Produits de dégradation de la fibrine et du fibrinogène.
- diagnostic : Infections à coronavirus, Thromboembolisme veineux.
- effets indésirables : Anticoagulants, Infections à coronavirus, Pneumopathie virale.
- induit chimiquement : Hémorragie.
- prévention et contrôle : Hémorragie, Thromboembolisme veineux.
- sang : Infections à coronavirus, Oedème pulmonaire, Pneumopathie virale, Thrombophilie.
- thérapie : Thromboembolisme veineux.
- traitement médicamenteux : Thrombophilie.
- usage thérapeutique : Anticoagulants.
- étiologie : Oedème pulmonaire, Thromboembolisme veineux, Thrombophilie.
- Analyse sur le lieu d'intervention, Betacoronavirus, Calendrier d'administration des médicaments, Dépistage de masse, Humains, Marqueurs biologiques, Pandémies, Patients hospitalisés, Post-cure, Prise en charge de la maladie, Sensibilité et spécificité, Soins de réanimation, Techniques de diagnostic cardiovasculaire, Techniques de laboratoire clinique.

English descriptors

KwdEn :
- Aftercare (MeSH), Anticoagulants (administration & dosage), Anticoagulants (adverse effects), Anticoagulants (therapeutic use), Betacoronavirus (MeSH), Biomarkers (MeSH), Clinical Laboratory Techniques (MeSH), Coronavirus Infections (blood), Coronavirus Infections (complications), Coronavirus Infections (diagnosis), Critical Care (MeSH), Cytokine Release Syndrome (blood), Cytokine Release Syndrome (etiology), Diagnostic Techniques, Cardiovascular (MeSH), Disease Management (MeSH), Drug Administration Schedule (MeSH), Fibrin Fibrinogen Degradation Products (analysis), Hemorrhage (chemically induced), Hemorrhage (prevention & control), Humans (MeSH), Inpatients (MeSH), Mass Screening (MeSH), Pandemics (MeSH), Pneumonia, Viral (blood), Pneumonia, Viral (complications), Point-of-Care Testing (MeSH), Pulmonary Edema (blood), Pulmonary Edema (etiology), Sensitivity and Specificity (MeSH), Thrombophilia (blood), Thrombophilia (drug therapy), Thrombophilia (etiology), Venous Thromboembolism (diagnosis), Venous Thromboembolism (etiology), Venous Thromboembolism (prevention & control), Venous Thromboembolism (therapy).
MESH :
- chemical , administration & dosage : Anticoagulants.
- chemical , adverse effects : Anticoagulants.
- chemical , analysis : Fibrin Fibrinogen Degradation Products.
- chemical , therapeutic use : Anticoagulants.
- blood : Coronavirus Infections, Cytokine Release Syndrome, Pneumonia, Viral, Pulmonary Edema, Thrombophilia.
- chemically induced : Hemorrhage.
- complications : Coronavirus Infections, Pneumonia, Viral.
- diagnosis : Coronavirus Infections, Venous Thromboembolism.
- drug therapy : Thrombophilia.
- etiology : Cytokine Release Syndrome, Pulmonary Edema, Thrombophilia, Venous Thromboembolism.
- prevention & control : Hemorrhage, Venous Thromboembolism.
- therapy : Venous Thromboembolism.
- Aftercare, Betacoronavirus, Biomarkers, Clinical Laboratory Techniques, Critical Care, Diagnostic Techniques, Cardiovascular, Disease Management, Drug Administration Schedule, Humans, Inpatients, Mass Screening, Pandemics, Point-of-Care Testing, Sensitivity and Specificity.

DOI: 10.1111/jth.14929
PubMed: 32459046
PubMed Central: PMC7283841

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 001089
to stream Main, to step Curation: 001089

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19.</title>
<author><name sortKey="Spyropoulos, Alex C" sort="Spyropoulos, Alex C" uniqKey="Spyropoulos A" first="Alex C" last="Spyropoulos">Alex C. Spyropoulos</name>
<affiliation wicri:level="2"><nlm:affiliation>Feinstein Institutes for Medical Research and The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, and Department of Medicine, Anticoagulation and Clinical Thrombosis Services, Northwell Health at Lenox Hill Hospital, New York, NY, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Feinstein Institutes for Medical Research and The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, and Department of Medicine, Anticoagulation and Clinical Thrombosis Services, Northwell Health at Lenox Hill Hospital, New York, NY</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Levy, Jerrold H" sort="Levy, Jerrold H" uniqKey="Levy J" first="Jerrold H" last="Levy">Jerrold H. Levy</name>
<affiliation wicri:level="2"><nlm:affiliation>Departments of Anesthesiology, Critical Care, and Surgery, Duke University School of Medicine, Durham, NC, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Departments of Anesthesiology, Critical Care, and Surgery, Duke University School of Medicine, Durham, NC</wicri:regionArea>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ageno, Walter" sort="Ageno, Walter" uniqKey="Ageno W" first="Walter" last="Ageno">Walter Ageno</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medicine and Surgery, University of Insubria, Varese, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Medicine and Surgery, University of Insubria, Varese</wicri:regionArea>
<wicri:noRegion>Varese</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Connors, Jean Marie" sort="Connors, Jean Marie" uniqKey="Connors J" first="Jean Marie" last="Connors">Jean Marie Connors</name>
<affiliation wicri:level="2"><nlm:affiliation>Hematology Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Hematology Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hunt, Beverley J" sort="Hunt, Beverley J" uniqKey="Hunt B" first="Beverley J" last="Hunt">Beverley J. Hunt</name>
<affiliation wicri:level="3"><nlm:affiliation>Thrombosis and Haemophilia Centre, Guy's and St Thomas' NHS Foundation Trust, London, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Thrombosis and Haemophilia Centre, Guy's and St Thomas' NHS Foundation Trust, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Iba, Toshiaki" sort="Iba, Toshiaki" uniqKey="Iba T" first="Toshiaki" last="Iba">Toshiaki Iba</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Emergency and Disaster Medicine, Juntendo University, Tokyo, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Emergency and Disaster Medicine, Juntendo University, Tokyo</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Levi, Marcel" sort="Levi, Marcel" uniqKey="Levi M" first="Marcel" last="Levi">Marcel Levi</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Medicine and Cardiometabolic Programme-NIHR UCLH/UCL BRC, University College London Hospitals NHS Foundation Trust, London, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Medicine and Cardiometabolic Programme-NIHR UCLH/UCL BRC, University College London Hospitals NHS Foundation Trust, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Samama, Charles Marc" sort="Samama, Charles Marc" uniqKey="Samama C" first="Charles Marc" last="Samama">Charles Marc Samama</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Anaesthesia, Intensive Care and Perioperative Medicine GHU AP-HP. Centre-Université de Paris-Cochin Hospital, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Anaesthesia, Intensive Care and Perioperative Medicine GHU AP-HP. Centre-Université de Paris-Cochin Hospital, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Thachil, Jecko" sort="Thachil, Jecko" uniqKey="Thachil J" first="Jecko" last="Thachil">Jecko Thachil</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Haematology, Manchester University Hospitals, Manchester, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Haematology, Manchester University Hospitals, Manchester</wicri:regionArea>
<placeName><settlement type="city">Manchester</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Manchester</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Giannis, Dimitrios" sort="Giannis, Dimitrios" uniqKey="Giannis D" first="Dimitrios" last="Giannis">Dimitrios Giannis</name>
<affiliation wicri:level="2"><nlm:affiliation>Feinstein Institutes for Medical Research, Manhasset, NY, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Feinstein Institutes for Medical Research, Manhasset, NY</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Douketis, James D" sort="Douketis, James D" uniqKey="Douketis J" first="James D" last="Douketis">James D. Douketis</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Medicine, McMaster University, Hamilton, ON, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, McMaster University, Hamilton, ON</wicri:regionArea>
<orgName type="university">Université McMaster</orgName>
<placeName><settlement type="city">Hamilton (Ontario)</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32459046</idno>
<idno type="pmid">32459046</idno>
<idno type="doi">10.1111/jth.14929</idno>
<idno type="pmc">PMC7283841</idno>
<idno type="wicri:Area/Main/Corpus">001089</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001089</idno>
<idno type="wicri:Area/Main/Curation">001089</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001089</idno>
<idno type="wicri:Area/Main/Exploration">001089</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19.</title>
<author><name sortKey="Spyropoulos, Alex C" sort="Spyropoulos, Alex C" uniqKey="Spyropoulos A" first="Alex C" last="Spyropoulos">Alex C. Spyropoulos</name>
<affiliation wicri:level="2"><nlm:affiliation>Feinstein Institutes for Medical Research and The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, and Department of Medicine, Anticoagulation and Clinical Thrombosis Services, Northwell Health at Lenox Hill Hospital, New York, NY, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Feinstein Institutes for Medical Research and The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, and Department of Medicine, Anticoagulation and Clinical Thrombosis Services, Northwell Health at Lenox Hill Hospital, New York, NY</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Levy, Jerrold H" sort="Levy, Jerrold H" uniqKey="Levy J" first="Jerrold H" last="Levy">Jerrold H. Levy</name>
<affiliation wicri:level="2"><nlm:affiliation>Departments of Anesthesiology, Critical Care, and Surgery, Duke University School of Medicine, Durham, NC, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Departments of Anesthesiology, Critical Care, and Surgery, Duke University School of Medicine, Durham, NC</wicri:regionArea>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ageno, Walter" sort="Ageno, Walter" uniqKey="Ageno W" first="Walter" last="Ageno">Walter Ageno</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medicine and Surgery, University of Insubria, Varese, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Medicine and Surgery, University of Insubria, Varese</wicri:regionArea>
<wicri:noRegion>Varese</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Connors, Jean Marie" sort="Connors, Jean Marie" uniqKey="Connors J" first="Jean Marie" last="Connors">Jean Marie Connors</name>
<affiliation wicri:level="2"><nlm:affiliation>Hematology Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Hematology Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hunt, Beverley J" sort="Hunt, Beverley J" uniqKey="Hunt B" first="Beverley J" last="Hunt">Beverley J. Hunt</name>
<affiliation wicri:level="3"><nlm:affiliation>Thrombosis and Haemophilia Centre, Guy's and St Thomas' NHS Foundation Trust, London, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Thrombosis and Haemophilia Centre, Guy's and St Thomas' NHS Foundation Trust, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Iba, Toshiaki" sort="Iba, Toshiaki" uniqKey="Iba T" first="Toshiaki" last="Iba">Toshiaki Iba</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Emergency and Disaster Medicine, Juntendo University, Tokyo, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Emergency and Disaster Medicine, Juntendo University, Tokyo</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Levi, Marcel" sort="Levi, Marcel" uniqKey="Levi M" first="Marcel" last="Levi">Marcel Levi</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Medicine and Cardiometabolic Programme-NIHR UCLH/UCL BRC, University College London Hospitals NHS Foundation Trust, London, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Medicine and Cardiometabolic Programme-NIHR UCLH/UCL BRC, University College London Hospitals NHS Foundation Trust, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Samama, Charles Marc" sort="Samama, Charles Marc" uniqKey="Samama C" first="Charles Marc" last="Samama">Charles Marc Samama</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Anaesthesia, Intensive Care and Perioperative Medicine GHU AP-HP. Centre-Université de Paris-Cochin Hospital, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Anaesthesia, Intensive Care and Perioperative Medicine GHU AP-HP. Centre-Université de Paris-Cochin Hospital, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Thachil, Jecko" sort="Thachil, Jecko" uniqKey="Thachil J" first="Jecko" last="Thachil">Jecko Thachil</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Haematology, Manchester University Hospitals, Manchester, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Haematology, Manchester University Hospitals, Manchester</wicri:regionArea>
<placeName><settlement type="city">Manchester</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Manchester</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Giannis, Dimitrios" sort="Giannis, Dimitrios" uniqKey="Giannis D" first="Dimitrios" last="Giannis">Dimitrios Giannis</name>
<affiliation wicri:level="2"><nlm:affiliation>Feinstein Institutes for Medical Research, Manhasset, NY, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Feinstein Institutes for Medical Research, Manhasset, NY</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Douketis, James D" sort="Douketis, James D" uniqKey="Douketis J" first="James D" last="Douketis">James D. Douketis</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Medicine, McMaster University, Hamilton, ON, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, McMaster University, Hamilton, ON</wicri:regionArea>
<orgName type="university">Université McMaster</orgName>
<placeName><settlement type="city">Hamilton (Ontario)</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of thrombosis and haemostasis : JTH</title>
<idno type="eISSN">1538-7836</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aftercare (MeSH)</term>
<term>Anticoagulants (administration & dosage)</term>
<term>Anticoagulants (adverse effects)</term>
<term>Anticoagulants (therapeutic use)</term>
<term>Betacoronavirus (MeSH)</term>
<term>Biomarkers (MeSH)</term>
<term>Clinical Laboratory Techniques (MeSH)</term>
<term>Coronavirus Infections (blood)</term>
<term>Coronavirus Infections (complications)</term>
<term>Coronavirus Infections (diagnosis)</term>
<term>Critical Care (MeSH)</term>
<term>Cytokine Release Syndrome (blood)</term>
<term>Cytokine Release Syndrome (etiology)</term>
<term>Diagnostic Techniques, Cardiovascular (MeSH)</term>
<term>Disease Management (MeSH)</term>
<term>Drug Administration Schedule (MeSH)</term>
<term>Fibrin Fibrinogen Degradation Products (analysis)</term>
<term>Hemorrhage (chemically induced)</term>
<term>Hemorrhage (prevention & control)</term>
<term>Humans (MeSH)</term>
<term>Inpatients (MeSH)</term>
<term>Mass Screening (MeSH)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (blood)</term>
<term>Pneumonia, Viral (complications)</term>
<term>Point-of-Care Testing (MeSH)</term>
<term>Pulmonary Edema (blood)</term>
<term>Pulmonary Edema (etiology)</term>
<term>Sensitivity and Specificity (MeSH)</term>
<term>Thrombophilia (blood)</term>
<term>Thrombophilia (drug therapy)</term>
<term>Thrombophilia (etiology)</term>
<term>Venous Thromboembolism (diagnosis)</term>
<term>Venous Thromboembolism (etiology)</term>
<term>Venous Thromboembolism (prevention & control)</term>
<term>Venous Thromboembolism (therapy)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Analyse sur le lieu d'intervention (MeSH)</term>
<term>Anticoagulants (administration et posologie)</term>
<term>Anticoagulants (effets indésirables)</term>
<term>Anticoagulants (usage thérapeutique)</term>
<term>Betacoronavirus (MeSH)</term>
<term>Calendrier d'administration des médicaments (MeSH)</term>
<term>Dépistage de masse (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Hémorragie (induit chimiquement)</term>
<term>Hémorragie (prévention et contrôle)</term>
<term>Infections à coronavirus (complications)</term>
<term>Infections à coronavirus (diagnostic)</term>
<term>Infections à coronavirus (sang)</term>
<term>Marqueurs biologiques (MeSH)</term>
<term>Oedème pulmonaire (sang)</term>
<term>Oedème pulmonaire (étiologie)</term>
<term>Pandémies (MeSH)</term>
<term>Patients hospitalisés (MeSH)</term>
<term>Pneumopathie virale (complications)</term>
<term>Pneumopathie virale (sang)</term>
<term>Post-cure (MeSH)</term>
<term>Prise en charge de la maladie (MeSH)</term>
<term>Produits de dégradation de la fibrine et du fibrinogène (analyse)</term>
<term>Sensibilité et spécificité (MeSH)</term>
<term>Soins de réanimation (MeSH)</term>
<term>Techniques de diagnostic cardiovasculaire (MeSH)</term>
<term>Techniques de laboratoire clinique (MeSH)</term>
<term>Thromboembolisme veineux (diagnostic)</term>
<term>Thromboembolisme veineux (prévention et contrôle)</term>
<term>Thromboembolisme veineux (thérapie)</term>
<term>Thromboembolisme veineux (étiologie)</term>
<term>Thrombophilie (sang)</term>
<term>Thrombophilie (traitement médicamenteux)</term>
<term>Thrombophilie (étiologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anticoagulants</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Anticoagulants</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Fibrin Fibrinogen Degradation Products</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anticoagulants</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anticoagulants</term>
</keywords>
<keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Produits de dégradation de la fibrine et du fibrinogène</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Coronavirus Infections</term>
<term>Cytokine Release Syndrome</term>
<term>Pneumonia, Viral</term>
<term>Pulmonary Edema</term>
<term>Thrombophilia</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Hemorrhage</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Coronavirus Infections</term>
<term>Venous Thromboembolism</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Thromboembolisme veineux</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Thrombophilia</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Anticoagulants</term>
<term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Cytokine Release Syndrome</term>
<term>Pulmonary Edema</term>
<term>Thrombophilia</term>
<term>Venous Thromboembolism</term>
</keywords>
<keywords scheme="MESH" qualifier="induit chimiquement" xml:lang="fr"><term>Hémorragie</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Hemorrhage</term>
<term>Venous Thromboembolism</term>
</keywords>
<keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Hémorragie</term>
<term>Thromboembolisme veineux</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Oedème pulmonaire</term>
<term>Pneumopathie virale</term>
<term>Thrombophilie</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Venous Thromboembolism</term>
</keywords>
<keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Thromboembolisme veineux</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Thrombophilie</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticoagulants</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Oedème pulmonaire</term>
<term>Thromboembolisme veineux</term>
<term>Thrombophilie</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aftercare</term>
<term>Betacoronavirus</term>
<term>Biomarkers</term>
<term>Clinical Laboratory Techniques</term>
<term>Critical Care</term>
<term>Diagnostic Techniques, Cardiovascular</term>
<term>Disease Management</term>
<term>Drug Administration Schedule</term>
<term>Humans</term>
<term>Inpatients</term>
<term>Mass Screening</term>
<term>Pandemics</term>
<term>Point-of-Care Testing</term>
<term>Sensitivity and Specificity</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Analyse sur le lieu d'intervention</term>
<term>Betacoronavirus</term>
<term>Calendrier d'administration des médicaments</term>
<term>Dépistage de masse</term>
<term>Humains</term>
<term>Marqueurs biologiques</term>
<term>Pandémies</term>
<term>Patients hospitalisés</term>
<term>Post-cure</term>
<term>Prise en charge de la maladie</term>
<term>Sensibilité et spécificité</term>
<term>Soins de réanimation</term>
<term>Techniques de diagnostic cardiovasculaire</term>
<term>Techniques de laboratoire clinique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32459046</PMID>
<DateCompleted><Year>2020</Year>
<Month>08</Month>
<Day>14</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>08</Month>
<Day>14</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-7836</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>18</Volume>
<Issue>8</Issue>
<PubDate><Year>2020</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Journal of thrombosis and haemostasis : JTH</Title>
<ISOAbbreviation>J. Thromb. Haemost.</ISOAbbreviation>
</Journal>
<ArticleTitle>Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19.</ArticleTitle>
<Pagination><MedlinePgn>1859-1865</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/jth.14929</ELocationID>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Spyropoulos</LastName>
<ForeName>Alex C</ForeName>
<Initials>AC</Initials>
<Identifier Source="ORCID">https://orcid.org/0000-0002-3175-461X</Identifier>
<AffiliationInfo><Affiliation>Feinstein Institutes for Medical Research and The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, and Department of Medicine, Anticoagulation and Clinical Thrombosis Services, Northwell Health at Lenox Hill Hospital, New York, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Levy</LastName>
<ForeName>Jerrold H</ForeName>
<Initials>JH</Initials>
<AffiliationInfo><Affiliation>Departments of Anesthesiology, Critical Care, and Surgery, Duke University School of Medicine, Durham, NC, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ageno</LastName>
<ForeName>Walter</ForeName>
<Initials>W</Initials>
<AffiliationInfo><Affiliation>Department of Medicine and Surgery, University of Insubria, Varese, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Connors</LastName>
<ForeName>Jean Marie</ForeName>
<Initials>JM</Initials>
<Identifier Source="ORCID">https://orcid.org/0000-0001-6445-582X</Identifier>
<AffiliationInfo><Affiliation>Hematology Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hunt</LastName>
<ForeName>Beverley J</ForeName>
<Initials>BJ</Initials>
<Identifier Source="ORCID">https://orcid.org/0000-0002-4709-0774</Identifier>
<AffiliationInfo><Affiliation>Thrombosis and Haemophilia Centre, Guy's and St Thomas' NHS Foundation Trust, London, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Iba</LastName>
<ForeName>Toshiaki</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>Department of Emergency and Disaster Medicine, Juntendo University, Tokyo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Levi</LastName>
<ForeName>Marcel</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Department of Medicine and Cardiometabolic Programme-NIHR UCLH/UCL BRC, University College London Hospitals NHS Foundation Trust, London, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Samama</LastName>
<ForeName>Charles Marc</ForeName>
<Initials>CM</Initials>
<AffiliationInfo><Affiliation>Department of Anaesthesia, Intensive Care and Perioperative Medicine GHU AP-HP. Centre-Université de Paris-Cochin Hospital, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Thachil</LastName>
<ForeName>Jecko</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Department of Haematology, Manchester University Hospitals, Manchester, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Giannis</LastName>
<ForeName>Dimitrios</ForeName>
<Initials>D</Initials>
<Identifier Source="ORCID">https://orcid.org/0000-0001-9246-976X</Identifier>
<AffiliationInfo><Affiliation>Feinstein Institutes for Medical Research, Manhasset, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Douketis</LastName>
<ForeName>James D</ForeName>
<Initials>JD</Initials>
<Identifier Source="ORCID">https://orcid.org/0000-0001-5288-0394</Identifier>
<AffiliationInfo><Affiliation>Department of Medicine, McMaster University, Hamilton, ON, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><CollectiveName>Subcommittee on Perioperative, Critical Care Thrombosis, Haemostasis of the Scientific, Standardization Committee of the International Society on Thrombosis and Haemostasis</CollectiveName>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D017065">Practice Guideline</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>J Thromb Haemost</MedlineTA>
<NlmUniqueID>101170508</NlmUniqueID>
<ISSNLinking>1538-7836</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005338">Fibrin Fibrinogen Degradation Products</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C036309">fibrin fragment D</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName>
<SupplMeshName Type="Protocol" UI="C000657964">COVID-19 diagnostic testing</SupplMeshName>
<SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000359" MajorTopicYN="N">Aftercare</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019411" MajorTopicYN="N">Clinical Laboratory Techniques</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003422" MajorTopicYN="N">Critical Care</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000080424" MajorTopicYN="N">Cytokine Release Syndrome</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003935" MajorTopicYN="N">Diagnostic Techniques, Cardiovascular</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019468" MajorTopicYN="N">Disease Management</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005338" MajorTopicYN="N">Fibrin Fibrinogen Degradation Products</DescriptorName>
<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName>
<QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007297" MajorTopicYN="N">Inpatients</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008403" MajorTopicYN="N">Mass Screening</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000067716" MajorTopicYN="N">Point-of-Care Testing</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011654" MajorTopicYN="N">Pulmonary Edema</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019851" MajorTopicYN="N">Thrombophilia</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D054556" MajorTopicYN="N">Venous Thromboembolism</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword>
<Keyword MajorTopicYN="N">anticoagulant</Keyword>
<Keyword MajorTopicYN="N">antithrombotic therapy</Keyword>
<Keyword MajorTopicYN="N">coronavirus disease 2019</Keyword>
<Keyword MajorTopicYN="N">hospitalization</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>04</Month>
<Day>23</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>05</Month>
<Day>15</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>05</Month>
<Day>21</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>5</Month>
<Day>28</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>8</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>5</Month>
<Day>28</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32459046</ArticleId>
<ArticleId IdType="doi">10.1111/jth.14929</ArticleId>
<ArticleId IdType="pmc">PMC7283841</ArticleId>
</ArticleIdList>
<ReferenceList><Title>REFERENCES</Title>
<Reference><Citation>Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506.</Citation>
</Reference>
<Reference><Citation>Novel Coronavirus (2019-nCoV) situation reports n.d. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. (Accessed March 17, 2020).</Citation>
</Reference>
<Reference><Citation>Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145-147.</Citation>
</Reference>
<Reference><Citation>Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18(6):1421-1424.</Citation>
</Reference>
<Reference><Citation>Obi AT, Tignanelli CJ, Jacobs BN, et al. Empirical systemic anticoagulation is associated with decreased venous thromboembolism in critically ill influenza A H1N1 acute respiratory distress syndrome patients. J Vasc Surg Venous Lymphat Disord. 2019;7:317-324.</Citation>
</Reference>
<Reference><Citation>Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol. 2020;127:104362.</Citation>
</Reference>
<Reference><Citation>Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J Am Coll Cardiol. 2020;75(18):2352-2371.</Citation>
</Reference>
<Reference><Citation>Spyropoulos AC, Raskob GE. New paradigms in venous thromboprophylaxis of medically ill patients. Thromb Haemost. 2017;117:1662-1670.</Citation>
</Reference>
<Reference><Citation>Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(5):1023-1026.</Citation>
</Reference>
<Reference><Citation>Bikdeli B, Lobo JL, Jiménez D, et al. Early use of echocardiography in patients with acute pulmonary embolism: findings from the RIETE registry. J Am Heart Assoc. 2018;7:e009042.</Citation>
</Reference>
<Reference><Citation>Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141:e195S-e226S.</Citation>
</Reference>
<Reference><Citation>Schünemann HJ, Cushman M, Burnett AE, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv. 2018;2:3198-3225.</Citation>
</Reference>
<Reference><Citation>Barbar S, Noventa F, Rossetto V, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost. 2010;8:2450-2457.</Citation>
</Reference>
<Reference><Citation>Spyropoulos AC, Anderson FA, FitzGerald G, et al. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest. 2011;140:706-714.</Citation>
</Reference>
<Reference><Citation>Greene MT, Spyropoulos AC, Chopra V, et al. Validation of risk assessment models of venous thromboembolism in hospitalized medical patients. Am J Med. 2016;129:1001.e9-1001.e18.</Citation>
</Reference>
<Reference><Citation>Mahan CE, Liu Y, Turpie AG, et al. External validation of a risk assessment model for venous thromboembolism in the hospitalised acutely-ill medical patient (VTE-VALOURR). Thromb Haemost. 2014;112:692-699.</Citation>
</Reference>
<Reference><Citation>Rosenberg D, Eichorn A, Alarcon M, McCullagh L, McGinn T, Spyropoulos AC. External validation of the risk assessment model of the international medical prevention registry on venous thromboembolism (IMPROVE) for medical patients in a tertiary health system. J Am Heart Assoc. 2014;3(6): e001152.</Citation>
</Reference>
<Reference><Citation>Wang T, Chen R, Liu C, et al. Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19. Lancet Haematol. 2020;7(5):e362-e363.</Citation>
</Reference>
<Reference><Citation>Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18:844-847.</Citation>
</Reference>
<Reference><Citation>Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094-1099.</Citation>
</Reference>
<Reference><Citation>Ho KM, Tan JA. Stratified meta-analysis of intermittent pneumatic compression of the lower limbs to prevent venous thromboembolism in hospitalized patients. Circulation. 2013;128:1003-1020.</Citation>
</Reference>
<Reference><Citation>Fu L, Wang B, Yuan T, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis. J Infect. 2020;80(6):656-665.</Citation>
</Reference>
<Reference><Citation>Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):1-8.</Citation>
</Reference>
<Reference><Citation>Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033-1034.</Citation>
</Reference>
<Reference><Citation>Fox S, Akmatbekov A, Harbert J, Li G, Brown J, Vander Heide RPulmonary and cardiac pathology in Covid-19: the first autopsy series from New Orleans. 2020;8(7):681-686.</Citation>
</Reference>
<Reference><Citation>Danzi GB, Loffi M, Galeazzi G, Gherbesi E. Acute pulmonary embolism and COVID-19 pneumonia: a random association? Eur Heart J. 2020;41(19):1858.</Citation>
</Reference>
<Reference><Citation>Wang J, Hajizadeh N, Moore EE, et al. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): a case series. J Thromb Haemost. 2020 ;18(7):1752-1755.</Citation>
</Reference>
<Reference><Citation>OBE BH, Retter A, McClintock C.Practical guidance for the prevention of thrombosis and management of coagulopathy and disseminated intravascular coagulation of patients infected with COVID-19 n.d. https://thrombosisuk.org/covid-19-thrombosis.php (accessed April 10, 2020).</Citation>
</Reference>
<Reference><Citation>Cohoon KP, Mahé G, Tafur AJ, Spyropoulos AC. Emergence of institutional antithrombotic protocols for coronavirus 2019. Res Pract Thromb Haemost. 2020;4(4):510-517.</Citation>
</Reference>
<Reference><Citation>MacDougall K, Spyropoulos AC. New paradigms of extended thromboprophylaxis in medically ill patients. J Clin Med. 2020;9(4):1002.</Citation>
</Reference>
<Reference><Citation>Cohen AT, Spiro TE, Büller HR, et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013;368:513-523.</Citation>
</Reference>
<Reference><Citation>Spyropoulos AC, Lipardi C, Xu J, et al. Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study. Clin Appl Thromb. 2019;25:107602961988602.</Citation>
</Reference>
<Reference><Citation>Hull RD, Schellong SM, Tapson VF, et al. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med. 2010;153:8-18.</Citation>
</Reference>
<Reference><Citation>Cohoon KP, Sanctis YD, Haskell L, McBane RD, Spiro TE. Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study. J Thromb Haemost. 2018;16:1278-1287.</Citation>
</Reference>
<Reference><Citation>Spyropoulos AC, Lipardi C, Xu J, et al. Modified IMPROVE VTE risk score and elevated d-dimer identify a high venous thromboembolism risk in acutely ill medical population for extended thromboprophylaxis. TH Open Companion J Thromb Haemost. 2020;4:e59-e65.</Citation>
</Reference>
<Reference><Citation>Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149:315-352.</Citation>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Canada</li>
<li>France</li>
<li>Italie</li>
<li>Japon</li>
<li>Royaume-Uni</li>
<li>États-Unis</li>
</country>
<region><li>Angleterre</li>
<li>Caroline du Nord</li>
<li>Grand Londres</li>
<li>Grand Manchester</li>
<li>Massachusetts</li>
<li>Ontario</li>
<li>Région de Kantō</li>
<li>État de New York</li>
<li>Île-de-France</li>
</region>
<settlement><li>Hamilton (Ontario)</li>
<li>Londres</li>
<li>Manchester</li>
<li>Paris</li>
<li>Tokyo</li>
</settlement>
<orgName><li>Université McMaster</li>
</orgName>
</list>
<tree><country name="États-Unis"><region name="État de New York"><name sortKey="Spyropoulos, Alex C" sort="Spyropoulos, Alex C" uniqKey="Spyropoulos A" first="Alex C" last="Spyropoulos">Alex C. Spyropoulos</name>
</region>
<name sortKey="Connors, Jean Marie" sort="Connors, Jean Marie" uniqKey="Connors J" first="Jean Marie" last="Connors">Jean Marie Connors</name>
<name sortKey="Giannis, Dimitrios" sort="Giannis, Dimitrios" uniqKey="Giannis D" first="Dimitrios" last="Giannis">Dimitrios Giannis</name>
<name sortKey="Levy, Jerrold H" sort="Levy, Jerrold H" uniqKey="Levy J" first="Jerrold H" last="Levy">Jerrold H. Levy</name>
</country>
<country name="Italie"><noRegion><name sortKey="Ageno, Walter" sort="Ageno, Walter" uniqKey="Ageno W" first="Walter" last="Ageno">Walter Ageno</name>
</noRegion>
</country>
<country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Hunt, Beverley J" sort="Hunt, Beverley J" uniqKey="Hunt B" first="Beverley J" last="Hunt">Beverley J. Hunt</name>
</region>
<name sortKey="Levi, Marcel" sort="Levi, Marcel" uniqKey="Levi M" first="Marcel" last="Levi">Marcel Levi</name>
<name sortKey="Thachil, Jecko" sort="Thachil, Jecko" uniqKey="Thachil J" first="Jecko" last="Thachil">Jecko Thachil</name>
</country>
<country name="Japon"><region name="Région de Kantō"><name sortKey="Iba, Toshiaki" sort="Iba, Toshiaki" uniqKey="Iba T" first="Toshiaki" last="Iba">Toshiaki Iba</name>
</region>
</country>
<country name="France"><region name="Île-de-France"><name sortKey="Samama, Charles Marc" sort="Samama, Charles Marc" uniqKey="Samama C" first="Charles Marc" last="Samama">Charles Marc Samama</name>
</region>
</country>
<country name="Canada"><region name="Ontario"><name sortKey="Douketis, James D" sort="Douketis, James D" uniqKey="Douketis J" first="James D" last="Douketis">James D. Douketis</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000647 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000647 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidFranceV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:32459046
   |texte=   Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:32459046" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidFranceV1

This area was generated with Dilib version V0.6.37.
Data generation: Tue Oct 6 23:31:36 2020. Site generation: Fri Feb 12 22:48:37 2021

	Serveur d'exploration sur la COVID en France
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la COVID en France

Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19.

Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19.

Source :

Descripteurs français

English descriptors

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki